Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis

New England Journal of Medicine

Volumn 343, Issue 16, 2000, Pages 1156-1162

  Chan, Tak Mao ^a   Li, Fu Keung ^a   Tang, Colin S O ^a   Wong, Raymond W S ^a   Fang, Guo Xiang ^a   Ji, Yu Lian ^a   Lau, Chak Sing ^a   Wong, Andrew K M ^a   Tong, Matthew K L ^a   Chan, Kwok Wah ^a   Lai, Kar Neng ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AMENORRHEA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEATH; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HAIR LOSS; HUMAN; INFECTION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT FAILURE; URINE SEDIMENT;

ADULT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; PREDNISOLONE; RECURRENCE; REMISSION INDUCTION;

EID: 0034687429     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200010193431604     Document Type: Article

References (15)

1. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide
2. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis
3. A controlled trial of plasmapheresis in severe lupus nephritis
4. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)
5. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection
6. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
7. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRL1pr/1pr mice
8. Attenuation of murine lupus nephritis by mycophenolate mofetil
9. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations
10. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide
11. Sequential therapy for diffuse proliferative and membranous lupus nephritis: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone
12. The 1982 revised criteria for the classification of systemic lupus erythematosus
13. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome
14. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs